Patents by Inventor Michael Saxe

Michael Saxe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MGLU2/3 ANTAGONISTS FOR THE TREATMENT OF INTELLECTUAL DISABILITIES
    Publication number: 20250017937
    Abstract: This invention relates to a new medical use for certain chemical compounds and pharmaceutical compositions containing them. The invention relates to compounds which are mGlu2/3 negative allosteric modulators for use in the treatment of intellectual disabilities. In another aspect, the invention relates to a pharmaceutical composition for use in the treatment of intellectual disabilities comprising a compound according to the invention and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: July 22, 2024
    Publication date: January 16, 2025
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Theresa M. BALLARD, Silvia Gatti MCARTHUR, Michael SAXE, Juergen WICHMANN, Thomas WOLTERING
  • MGLU2/3 ANTAGONISTS FOR THE TREATMENT OF INTELLECTUAL DISABILITIES
    Publication number: 20190343839
    Abstract: This invention relates to a new medical use for certain chemical compounds and pharmaceutical compositions containing them. The invention relates to compounds which are mGlu2/3 negative allosteric modulators for use in the treatment of intellectual disabilities. In another aspect, the invention relates to a pharmaceutical composition for use in the treatment of intellectual disabilities comprising a compound according to the invention and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: April 17, 2019
    Publication date: November 14, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Theresa M. BALLARD, Silvia Gatti MCARTHUR, Michael SAXE, Juergen WICHMANN, Thomas WOLTERING
  • MGLU2/3 ANTAGONISTS FOR THE TREATMENT OF INTELLECTUAL DISABILITIES
    Publication number: 20180235971
    Abstract: The invention relates to compounds which are mGlu2/3 negative allosteric modulators for use in the treatment of intellectual disabilities. In another aspect, the invention relates to a pharmaceutical composition for use in the treatment of intellectual disabilities comprising a compound according to the invention and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: April 25, 2018
    Publication date: August 23, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Theresa M. Ballard, Silvia Gatti McArthur, Michael Saxe, Juergen Wichmann, Thomas Woltering
  • MGLU2/3 ANTAGONISTS FOR THE TREATMENT OF AUTISTIC DISORDERS
    Publication number: 20170173022
    Abstract: This invention relates to a new medical use for certain chemical compounds and pharmaceutical compositions containing them. The invention relates to compounds which are mGlu2/3 negative allosteric modulators for use in the treatment of Autistic Spectrum Disorder (ASD), in particular, autism. In another aspect, the invention relates to a pharmaceutical composition for use in the treatment of ASD comprising a compound according to the invention and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: November 30, 2016
    Publication date: June 22, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Silvia Gatti McArthur, Michael Saxe, Juergen Wichmann, Thomas Woltering
  • MGLU2/3 ANTAGONISTS FOR THE TREATMENT OF INTELLECTUAL DISABILITIES
    Publication number: 20170035767
    Abstract: The invention relates to compounds which are mGlu2/3 negative allosteric modulators for use in the treatment of intellectual disabilities. In another aspect, the invention relates to a pharmaceutical composition for use in the treatment of intellectual disabilities comprising a compound according to the invention and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: October 21, 2016
    Publication date: February 9, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Theresa M. Ballard, Silvia Gatti McArthur, Michael Saxe, Juergen Wichmann, Thomas Woltering
  • MGLU2/3 ANTAGONISTS FOR THE TREATMENT OF AUTISTIC DISORDERS
    Publication number: 20150252049
    Abstract: This invention relates to a new medical use for certain chemical compounds and pharmaceutical compositions containing them. The invention relates to compounds which are mGlu2/3 negative allosteric modulators for use in the treatment of Autistic Spectrum Disorder (ASD), in particular, autism. In another aspect, the invention relates to a pharmaceutical composition for use in the treatment of ASD comprising a compound according to the invention and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: April 23, 2015
    Publication date: September 10, 2015
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Silvia Gatti McArthur, Michael Saxe, Juergen Wichmann, Thomas Woltering
  • Brain progenitor cell-based assay, and related methods and compositions
    Publication number: 20040247525
    Abstract: This invention provides methods for determining whether an agent increases brain progenitor cell division in a subject. Furthermore, this invention provides methods for treating anxiety, depression, a cognitive disorder or a neuro-degenerative disorder or inhibiting the onset of anxiety, depression or a cognitive disorder by administering to an afflicted subject a therapeutically or prophylactically effective amount of the agent. Finally, this invention provides methods for treating anxiety, depression, a cognitive disorder or a neuro-degenerative disorder or inhibiting the onset of anxiety, depression or a cognitive disorder by administering to an afflicted subject a therapeutically or prophylactically effective amount of Hh-Ag 1.1, Hh-Ag 1.2, Hh-Ag 1.3, or a derivative of Hh-Ag 1.1, Hh-Ag 1.2 or Hh-Ag 1.3.
    Type: Application
    Filed: January 22, 2004
    Publication date: December 9, 2004
    Inventors: Rene Hen, Luca Santarelli, Michael Saxe